Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI-Assisted Tissue Sample Analytics Model Speeds Up Breast Cancer Diagnostics

By LabMedica International staff writers
Posted on 31 May 2022

The field of pathology is undergoing a paradigm shift. More...

Pathologists have relied on the same cumbersome and bias-prone technology for the past 150 years; manual slide analysis with microscopes for tasks like evaluating patient samples to aid cancer diagnostics. Researchers are working to provide tools to overcome the challenges these traditional methods pose. Through automation and digital tools clinical pathology labs can increase the speed and accuracy of their work, thereby enabling patients to receive diagnoses and treatment plans faster while also alleviating the strain on pathologists. Deep learning AI has the potential to bring speed and accuracy to sample evaluation and diagnostics. Now, a novel AI tool can improve prognostic and predictive evaluation in breast cancer diagnostics through its unique functionalities.

The majority of breast cancer cases express estrogen receptor (ER) and/or progesterone receptor (PR). Therefore, the two are considered to be the most significant biomarkers involved in the evaluation of breast cancer. Aiforia Technologies Plc’s (Cambridge, MA, USA) Clinical AI Model for Breast Cancer; ER is an AI model that automates the calculation of ER - a group of proteins present in the majority of breast cancers, therefore a vital biomarker in its diagnosis, as well as a commonly used predictive factor for treatment and prognostic factor for survival in breast cancer. The Aiforia Clinical AI Model for Breast Cancer; PR automates the detection of tumor areas as well as the calculation of PR-positive and negative cells from whole slide images (WSIs) and selected areas and even the viewing and selection of areas with high PR-positive density, or hotspots. The AI-assisted image analysis results are available with speed and consistency. Aiforia currently offers three CE-IVD marked clinical AI models for breast cancer diagnostics as well as the CE-IVD marked PD-L1 AI model for lung cancer diagnostics.

“Since ER and PR positivity in breast cancer are both always measured, it was only natural to develop a model for the detection of PR positive tumor cells as well. It has to be acknowledged that the biomarker, PR's, expression is dependent on the ER biomarker as well,” explained Dr. Nelli Sjöblom MD, Consulting Pathologist at Aiforia Technologies. “However, it still has independent prognostic value and is associated with for example the tumor grade. Breast cancers with ER and/or PR positivity have a lower risk of recurrence of the disease so it is imperative to identify these patients reliably to be able to choose the right therapeutic option.”

Related Links:
Aiforia Technologies Plc 


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Collection and Transport System
PurSafe Plus®
New
Gel Cards
DG Gel Cards
New
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Ultrasensitive NeXT Personal Test detects the earliest molecular signs of recurrence in breast cancer patients (Photo courtesy of Personalis)

Ultrasensitive Test Could Identify Earliest Molecular Signs of Metastatic Relapse in Breast Cancer Patients

HR+ (hormone receptor-positive) HER2- (human epidermal growth factor receptor 2-negative) breast cancer represents over 70% of all breast cancer cases and carries a significant risk of late recurrence.... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.